Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Zhiqin Dai"'
Autor:
Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Yan Wang, Xiaoxiang Chen
Publikováno v:
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-9 (2021)
Abstract Background Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monoth
Externí odkaz:
https://doaj.org/article/8341992b602f422d93136f6ee5d9f6e3
Publikováno v:
OncoTargets and Therapy. 13:9857-9863
Purpose Survival of platinum-resistant ovarian cancer (PROC) patients is significantly shortened to around 12 months. Anlotinib is a new multi-target tyrosine kinase inhibitor. The goal of this study is to evaluate the efficacy and safety of anlotini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7217ae76f027d2bad4a3051f3f2f51b9
https://doi.org/10.2147/ott.s268613
https://doi.org/10.2147/ott.s268613
Autor:
Minmin Yu, Hongmei Zhang, Xiaoyan Ying, Baozhen Xu, Songlin Xue, Rong Zhang, Hui Yang, Zhiqin Dai
Publikováno v:
Cancer Management and Research. 11:6511-6519
Background: Cervical cancer is one of the most lethal malignancies among women in the world. Every year about 311,365 women die because of cervical cancer. Chemo-resistance is the main reason of the lethal malignancies, and the mechanism of chemo-res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73973ffe1dd63568f38698d396ebe6af
https://doi.org/10.2147/cmar.s199659
https://doi.org/10.2147/cmar.s199659
Autor:
Zhiqin Dai, Yan Wang, Rui Zhou, Jing Ni, Xia Xu, Xianzhong Cheng, Qian Zhao, Xiaoxiang Chen, Wenwen Guo, Hongyuan Gu
Publikováno v:
Journal of Ovarian Research
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-9 (2021)
Journal of Ovarian Research, Vol 14, Iss 1, Pp 1-9 (2021)
Background Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monotherapy in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b2695473f9629041609e158c2e5691a
https://doi.org/10.1186/s13048-021-00803-2
https://doi.org/10.1186/s13048-021-00803-2
Autor:
Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, xiaoxiang chen
BackgroundNiraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monotherapy in B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::812644f433bb009bed8b0feb4d441bbc
https://doi.org/10.21203/rs.3.rs-101839/v1
https://doi.org/10.21203/rs.3.rs-101839/v1
Autor:
Minmin, Yu, Baozhen, Xu, Hui, Yang, Songlin, Xue, Rong, Zhang, Hongmei, Zhang, Xiaoyan, Ying, Zhiqin, Dai
Publikováno v:
Cancer Management and Research
Background: Cervical cancer is one of the most lethal malignancies among women in the world. Every year about 311,365 women die because of cervical cancer. Chemo-resistance is the main reason of the lethal malignancies, and the mechanism of chemo-res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cb0e19fea85dca53d6b3d12f2ed9f858
https://pubmed.ncbi.nlm.nih.gov/31372052
https://pubmed.ncbi.nlm.nih.gov/31372052
Autor:
Zhiqin Dai, Lingya Pan, Hong Huang, Wantao Ying, Jie Yin, Ming Chen, Xiaohong Qian, Ning Mao, Xin Liu, Haojie He
Publikováno v:
Cancer Science
Paclitaxel resistance is a major obstacle for the treatment of ovarian cancer. The chemoresistance mechanisms are partly related to the mitochondria. Identification of the relevant proteins in mitochondria will help in clarifying the possible mechani
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a612a22abf01b3666bad1a521aa7b94
http://europepmc.org/articles/PMC4556398
http://europepmc.org/articles/PMC4556398
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 26(9)
ObjectiveThe purpose of this study was to build a video endoscopic inguinal lymphadenectomy (VEIL) via the 3-incision superolateral inguinal approach and explore the feasibility and significance of this method for vulvar cancer.MethodsThirty-seven pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c59c69ebc34fe2c0504b1a80b708a498
https://pubmed.ncbi.nlm.nih.gov/27575632
https://pubmed.ncbi.nlm.nih.gov/27575632
Publikováno v:
PROTEOMICS. 10:3789-3799
Resistance to platinum-based chemotherapy is the major obstacle to successful treatment of ovarian cancer. It is evident that mitochondrial defects and the dysfunctions of oxidative phosphorylation and energy production in ovarian cancer cells were d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab5b48002f61427c10bcacb5d230f231
https://doi.org/10.1002/pmic.200900685
https://doi.org/10.1002/pmic.200900685
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Background There is no consensus regarding the secondary cytoreduction surgery (CRS) in recurrent ovarian cancer patients. The present study aims to determine the value of secondary CRS and the eligible subgroup for this procedure. Methods 96 platinu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::849b2cca404543090abb482ae724f5db
http://europepmc.org/articles/PMC3847054
http://europepmc.org/articles/PMC3847054